Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study
Open Access
- 20 June 2019
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-9
Abstract
Ferric citrate hydrate (FC) is an iron-based phosphate binder approved for hyperphosphataemia in patients with chronic kidney disease. We conducted a randomised controlled trial to evaluate the effects of FC on anaemia management in haemodialysis patients with hyperphosphataemia. We 1:1 randomised 93 patients who were undergoing haemodialysis and being treated with non-iron-based phosphate binders and erythropoiesis-stimulating agents (ESA) to receive 24 weeks of FC or to continue their non-iron-based phosphate binders (control) in a multicentre, open-label, parallel-design. Phosphate level was controlled within target range (3.5–6.0 mg/dL). The primary endpoint was change in ESA dose from baseline to end of treatment. Secondary endpoints were changes in red blood cell, iron and mineral, and bone-related parameters. Compared with control, FC reduced ESA dose [mean change (SD), −1211.8 (3609.5) versus +1195 (6662.8) IU/week; P = 0.03] without significant differences in haemoglobin. FC decreased red blood cell distribution width (RDW) compared with control. While there were no changes in serum phosphate, FC reduced C-terminal fibroblast growth factor (FGF) 23 compared with control. The incidence of adverse events did not differ significantly between groups. Despite unchanged phosphate and haemoglobin levels, FC reduced ESA dose, RDW, and C-terminal FGF23 compared with control.Keywords
This publication has 27 references indexed in Scilit:
- Hepcidin-25 in Chronic Hemodialysis Patients Is Related to Residual Kidney Function and Not to Treatment with Erythropoiesis Stimulating AgentsPLOS ONE, 2012
- Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patientsNephrology Dialysis Transplantation, 2010
- Erythropoietic Response and Outcomes in Kidney Disease and Type 2 DiabetesNew England Journal of Medicine, 2010
- Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trialNephrology Dialysis Transplantation, 2010
- Plasma hepcidin is a modest predictor of dietary iron bioavailability in humans, whereas oral iron loading, measured by stable-isotope appearance curves, increases plasma hepcidinThe American Journal of Clinical Nutrition, 2009
- Hepcidin—A Potential Novel Biomarker for Iron Status in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal diseaseKidney International, 2009
- Erythropoiesis‐stimulating agent hyporesponsiveness (Review Article)Nephrology, 2007
- Clinical Aspects of Iron Use in the Anemia of Kidney DiseaseJournal of the American Society of Nephrology, 2007
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004